|
Media Releases |
Financial Reports |
Presen-tations |
|
10/02/2007
|
|
|
|
| Lonza Announces the Successful Start-up of its Small Scale Plant in China. |
Basel, 02.10.2007 - Lonza announces the successful start-up of the Small Scale Plant (SSP) in Nansha Guangzhou, China on 24 September 2007. After having accomplished a five-day process on schedule, the product was tested and met all the standards and requirements.
The Nansha facility, which operates under cGMP conditions, is designed to accommodate a greater number of reactors including a dedicated and technologically advanced Quality Control lab capable of fulfilling the ever increasing requirements of the global regulatory authorities on the highest possible level. In the completed first build-out phase, further smaller reactors including distillation and filtration units are installed, capable of handing a broad range of technologies. The configuration ensures fast change over, optimized efficiencies and extremely rapid technical transfer to commercial assets. Additional capacity can be added without impacting the running operations.
The plant is designed for production of quantities from 10 kilograms up to several hundreds of kilograms, and closes the gap between Nansha's kilo lab and commercial production assets to allow complete life-cycle support for pharmaceutical products out of China. The commercial scale API (active pharmaceutical ingredients) facility in Nansha is currently under construction and will go online in the second half of 2008.
The successfully realized batch is another milestone for Lonza to continually execute its strategic growth plan in China.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006, Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.
For further information:
Investor / Media Relations Lonza
Janet White
Tel +41 61 316 8566
Fax +41 61 316 9566
janet.white@lonza.com
Media Relations Lonza
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com
Investor Relations Lonza
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835
alexandre.pasini@lonza.com
|
|
|
